Sin Nombre virus full-length M segment-based DNA vaccines
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorJay Hooper
Life of this patent
Estimating the term…
Abstract
The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Claims9
An immunizing composition capable of inducing a high titer neutralizing antibody response against Sin Nombre Virus Gc and Gn glycoproteins, which composition comprises
- (i) a recombinant plasmid DNA capable of expressing the SNV Gc and Gn glycoproteins,
- wherein the plasmid DNA contains a modified codon optimized M gene selected
- from the group consisting of SEQ ID NO:1, 2 or 3, operably linked to a promoter
- that results in expression of the Gc and Gn glycoproteins, and
- (ii) a pharmacologically acceptable carrier.
Dependencies are inferred from the claim text.